Drugmakers Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca must face a lawsuit from two health centers accusing them of ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

The Department of Health and Human Services is terminating around $500 million in BARDA contracts associated with mRNA ...

Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...

The Second Circuit revived an antitrust case Wednesday against AstraZeneca Plc and three other pharmaceutical firms, saying ...

US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

The decision to cancel almost $500 million dollars in U.S. funding for the development of messenger RNA vaccines is dangerous ...

Baghdad (IraqiNews.com) – The Iraqi Ministry of Health mentioned on Sunday that the agreement with Sanofi, a French ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its ...

Just days after telling AstraZeneca how proud he was at its $50 billion investment strategy for the US, President Donald ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing a phase 1 vaccine candidate to expand its RSV pipeline beyond mRNA.